Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through new blockbuster drug molecules for a large class of diseases. Micar Innovation focuses on non-clinical Proof-of-Concepts (POCs) in preclinical R&D and Hit-to-Lead (H2L) achievements in areas such as neuroscience, oncology, cardio-vascularity, dermatology, rare diseases. Micar21 is our drug discovery platform for small molecule drug candidates. The business model is based on licensing our intellectual property to commercial partners and on the creation new spin out companies.

Micar Innovation received the CIDIC award for its well-chosen positioning in a complex and long value chain, where it can create key-value contributions by delivering non-clinical POCs. The company can be qualified as a fountain of intellectual property and an IP broker for new pharma startups and big pharma industry.

Discover our Pipeline

We have our own drug discovery programs and our lead compounds are already in Drug Discovery & Preclinical studies. Our strategy is to develop drug for both: humans and companion animals.
*It takes about 7-12 months to obtain a license for companion animals drug.

Project: 22 new treatments of rare and ultra rare diseases by 2022

JOIN US

Innovative most fast & accurate structure based in silico drug design and Artificial intelligence (AI)

Micar Innovation provide in silico screening for the detection of biologically active compounds / discovers new small molecule drugs through power of Artificial intelligence (AI), we offer a combination of the most advanced approaches currently used ...

Micar Innovation is a small molecule pharmaceutical incubator. Our focus is creating high-value therapies with transformative potential to address diseases and disorders with significant unmet need.

Translating breakthrough scientific insights into novel therapies

Order now our Drug Discovery Services